癌分子医学专题 |
|
|
|
|
zeste基因增强子同源物2抑制剂GSK126对前列腺癌细胞的作用及机制 |
林伟仁1, 陈亚天2, 曾玲晖2, 应荣彪1, 朱锋2 |
1. 浙江省台州市肿瘤医院内科, 浙江 温岭 317502;
2. 浙江大学城市学院医学院, 浙江 杭州 310015 |
|
Effect of a novel EZH2 inhibitor GSK126 on prostate cancer cells |
LIN Weiren1, CHEN Yatian2, ZENG Linghui2, YING Rongbiao1, ZHU Feng2 |
1. Department of Internal Medicine, Taizhou Cancer Hospital, Wenling 317502, China;
2. School of Medicine, Zhejiang University City College, Hangzhou 310015, China |
[1] |
LUNGLMAYR G. Efficacy and tolerability of Casodex in patients with advanced prostate cancer. International Casodex Study Group[J]. Anticancer Drugs, 1995,6(4): 508-513.
|
[2] |
SHI Y, LAN F, MATSON C, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1[J]. Cell, 2004, 119(7): 941-953.
|
[3] |
CHEN Y, YANG Y, WANG F, et al. Crystal structure of human histone lysine-specific demethylase 1(LSD1)[J]. Proc Natl Acad Sci U S A, 2006, 103(38): 13956-13961.
|
[4] |
YOU J S, JONES P A. Cancer genetics and epigenetics: two sides of the same coin?[J]. Cancer Cell, 2012, 22(1): 9-20.
|
[5] |
SHEN L, CUI J, LIANG S, et al. Update of research on the role of EZH2 in cancer progression[J]. Onco Targets Ther, 2013, 6(2): 321-324.
|
[6] |
REN G, BARITAKI S, MARATHE H, et al. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer[J]. Cancer Res, 2012,72(12): 3091-3104.
|
[7] |
MCCABE M T, OTT H M, GANJI G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations[J]. Nature, 2012, 492(7427): 108-112.
|
[8] |
SATO T, KANEDA A, TSUJI S, et al. PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer[J]. Sci Rep, 2013, 3(5): 1911.
|
[9] |
WU C, JIN X, YANG J, et al. Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer[J]. Oncotarget, 2016, 7(3):3440-3452.
|
[10] |
CHEN H, TU S W, HSIEH J T. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer[J]. J Biol Chem, 2005, 280(23): 22437-22444.
|
[11] |
CHEN Y T, ZHU F, LIN W R, et al. The novel EZH2 inhibitor, GSK126, suppresses cell migration and angiogenesis in via down regulating VEGF-A[J]. Cancer Chemother Pharmacol, 2016, 77(4):757-765.
|
[12] |
YU J M, SUN W, HUA F, et al. BCL6 induces EMT by promoting the ZEB1-mediated transcription repression of E-cadherin in breast cancer cells[J]. Cancer Lett, 2015, 365(2): 190-200.
|
[13] |
YU J, CAO Q, YU J, et al. The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer[J]. Oncogene, 2010, 29(39): 5370-5380.
|
[14] |
Mcgarvey K M, Greene E, Fahrner J A, et al. DNA methylation and complete transcriptional silencing of cancer genes persist after depletion of EZH2[J]. Cancer Res, 2007, 67(11): 5097-5102.
|
[15] |
陆虹昊, 马俐君. 上皮间质细胞转化的分子机制及其在肿瘤转移中的作用[J]. 中国肿瘤生物治疗杂志, 2009, 16(5): 541-545. LU Honghao, MA Lijun. The mechanism of epithelial-mesenchymal transition and its effect in tumor metastasis[J]. Chinese Journal of Cancer Biotherapy,2009, 16(5): 541-545. (in Chinese)
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|